Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Lord

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
Cellular Immunology|May 1, 1990
Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfectionK M Cerosaletti, T M Blieden, L W Harwell, et al.
Journal of Immunological Methods|August 23, 2001
T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopesM J Turner, C S Abdul-Alim, R A Willis, et al.
Cellular Immunology|October 15, 1995
Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumorA J McAdam, B A Pulaski, E Storozynsky, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1996
Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumorsK M Laughlin, S M Evans, W T Jenkins, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 16, 1996
Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cellsB A Pulaski, K Y Yeh, N Shastri, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1994
Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytesA J McAdam, A Felcher, M L Woods, et al.
British Journal of Cancer|March 25, 2000
Alteration of tumour response to radiation by interleukin-2 gene transferJ Lee, J P Moran, B M Fenton, et al.
International Journal of Molecular Medicine|December 19, 1998
Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genesC Wei, B P Callahan, M J Turner, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 1997
Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapyC Wei, R A Willis, B R Tilton, et al.
Cellular Immunology|October 15, 1995
B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinomaK Y Yeh, B A Pulaski, M L Woods, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Cellular Immunology|May 1, 1990
Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfectionK M Cerosaletti, T M Blieden, L W Harwell, et al.
Journal of Immunological Methods|August 23, 2001
T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopesM J Turner, C S Abdul-Alim, R A Willis, et al.
Cellular Immunology|October 15, 1995
Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumorA J McAdam, B A Pulaski, E Storozynsky, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1996
Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumorsK M Laughlin, S M Evans, W T Jenkins, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 16, 1996
Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cellsB A Pulaski, K Y Yeh, N Shastri, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1994
Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytesA J McAdam, A Felcher, M L Woods, et al.
British Journal of Cancer|March 25, 2000
Alteration of tumour response to radiation by interleukin-2 gene transferJ Lee, J P Moran, B M Fenton, et al.
International Journal of Molecular Medicine|December 19, 1998
Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genesC Wei, B P Callahan, M J Turner, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 1997
Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapyC Wei, R A Willis, B R Tilton, et al.
Cellular Immunology|October 15, 1995
B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinomaK Y Yeh, B A Pulaski, M L Woods, et al.
Pageof 11